The letter from Badve [1] relating to the series on preinvasive breast disease, published in the September and November issues of Breast Cancer Research [2] [3] [4] [5] [6] [7] [8] [9] [10] , is timely and very welcome. It rightly points out that one should be careful in changing classification systems based on limited knowledge and that perhaps discarding the term atypical ductal hyperplasia at the present time may be premature. I completely agree with him; however, there are a few issues I feel obliged to clarify.
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Many of the authors writing in this series (Stuart Schnitt, Hans Peterse, Sunil Lakhani, Ian Ellis) are also members of the World Health Organisation panel involved in the 'blue book' on classification of breast disease [11] . In this publication, the term atypical ductal hyperplasia has been retained for exactly the reasons stated by Badve, and the panel came to the consensus that at the present time discarding the traditional classification was premature.
The series produced here is not a consensus statement. They are a series of articles that is designed to educate with regards to current thinking, difficulties and problems of classification and evolving concepts as well as highlighting differences in practice. On behalf of the authors I thank Badve for saying that 'the articles are well written', but his criticism that the articles are in places contradictory is misplaced since this was exactly the intention.
Finally, although I completely agree with the view that it may be premature to discard the term atypical ductal hyperplasia, the arguments he uses to justify this relating to loss of heterozygosity analysis are incorrect. It is not true that 'two mutually contradictory conclusions can be drawn from this [loss of heterozygosity analysis in preinvasive disease and normal tissues] data'. It is not simply the presence or absence of loss of heterozygosity that has been used to support the concept of multistep progression. It is the presence/absence of loss of heterozygosity, the chromosomal regions involved, the frequency of alterations, the morphological similarities and transitions observed, and the data from a variety of molecular studies supporting relationships between lesions that have been used to construct a model of tumourigenesis. It is not true that finding loss of heterozygosity in normal tissues invalidates such a model and is therefore 'of no significance'. Badve is correct in stating that molecular data should not be overinterpreted to support changing the current classification systems, but by the same token care should be exercised not to use the data out of context to support an alternative view.
